Ropocamptide

Summary

Ropocamptide (also known as CLS001, MBI 226, Omiganan) is an investigational synthetic antimicrobial peptide that has shown in vitro activity against multidrug‑resistant bacteria and can act synergistically with certain antibiotics. The same designation is used for an iPSC‑derived corneal endothelial cell product (CLS001) investigated for topical transplantation to treat bullous keratopathy. Both applications are still experimental and are administered locally, either as a topical formulation or as a surgical cell graft.

Mechanism of Action

The peptide component of Ropocamptide displays direct bactericidal activity, likely through interaction with bacterial membranes that enhances permeability and facilitates the action of co‑administered antibiotics such as vancomycin or azithromycin. Electron microscopy showed no major structural damage, suggesting a molecular‑level synergistic mechanism. In the corneal cell‑therapy context, CLS001 consists of iPSC‑derived endothelial cells that integrate into the host corneal endothelium, re‑establishing barrier and pump functions to reduce stromal edema.

What the Research Shows

A 2017 in‑vitro study evaluated DP7 (Ropocamptide) against clinical isolates of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and Escherichia coli. The peptide showed high antimicrobial activity (MIC ≤32 mg/L) and, when combined with vancomycin or azithromycin, produced synergistic effects, especially in strains harboring multiple azithromycin‑resistance genes. Transmission electron microscopy revealed no notable morphological changes, implying a molecular interaction rather than gross membrane disruption. A 2025 first‑in‑human trial of the CLS001 corneal endothelial cell substitute in patients with bullous keratopathy reported improved visual acuity and reduced corneal edema, with no adverse events observed over a 12‑month follow‑up. Whole‑genome analyses were largely negative, though a de novo EP300 exon22 deletion was identified without clinical consequence.

Reported Benefits

In antimicrobial assays, Ropocamptide enhances the efficacy of existing antibiotics against highly resistant bacterial strains, potentially expanding treatment options. In ophthalmology, the CLS001 cell graft restores corneal endothelial function, leading to measurable visual improvement and resolution of stromal edema without the need for donor tissue, offering a novel therapeutic avenue for bullous keratopathy.

Limitations of the Evidence

Antimicrobial findings are confined to laboratory studies; no clinical infection trials have been reported, and the precise molecular mechanism remains undefined. The corneal cell‑therapy evidence stems from a single, small‑scale investigator‑initiated study with limited follow‑up; long‑term safety, efficacy across diverse patient populations, and regulatory approval status are still unknown. The observed EP300 mutation underscores the need for extensive genomic monitoring.

Safety Considerations

The antimicrobial study did not assess human toxicity, so safety in patients is uncharacterized. The corneal transplant study reported no adverse events up to one year, but the detection of a novel EP300 deletion raises theoretical concerns about genomic stability. Ongoing surveillance for delayed complications or immunogenic responses is warranted.

How It Is Administered

Ropocamptide is intended for topical application, though specific formulation details are not provided in the literature. The CLS001 corneal endothelial product is delivered surgically as a cell graft implanted onto the posterior corneal surface during a transplantation procedure.

Routes of Administration

Goals & Uses

• Broad-spectrum topical antimicrobial activityAnti InfectiveModerate
• Treatment of rosaceaDermatologyModerate
• Treatment of atopic dermatitisImmunology / DermatologyLow
• Acne vulgaris treatmentDermatologyLow
• Prevention of catheter-related bloodstream infectionsAnti Infective / ProphylaxisModerate

Contraindications

• Known hypersensitivity to omiganan or related peptidesAllergyHigh
• Application to open wounds or mucous membranes (unless studied)SafetyModerate

Adverse Effects

• Local skin irritationDermatologicalCommon
• Skin drynessDermatologicUncommon
• PruritusDermatologicCommonItching
• Contact dermatitisDermatologicalUncommon

Drug Interactions

• Other topical antimicrobialsLow

Population Constraints

• Pediatric populationsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Patients with compromised skin barrierDisease RelatedRelative

Regulatory Status

• European UnionInvestigationalNo EMA approval; clinical trials conducted in European centers.
• United StatesInvestigationalNo FDA approval; investigated under IND for catheter antisepsis and dermatological conditions.
• United KingdomUnknownNo known MHRA approval; regulatory status post-Brexit not specifically documented.

Ropocamptide has not received FDA or EMA approval as of the knowledge cutoff. It completed Phase III trials for catheter-site antisepsis (sponsored by Cadence Pharmaceuticals/Migenix) without gaining approval. More recent development has focused on dermatological indications under different sponsors.

Evidence & Sources

• Synergistic effects of antimicrobial peptide DP7 combined with antibiotics against multidrug-resistant bacteria
  Journal ArticleLowWu X, et al.2017-01-01T00:00:00.000000Z
• A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous keratopathy
  Journal ArticleLowHirayama M, et al.2025-01-01T00:00:00.000000Z

Frequently Asked Questions